Literature DB >> 1322156

Plasminogen receptors on rat colon carcinoma cells.

M Durliat1, O Komano, P Correc, O Bertrand, S Cochet, A Caignard, F Martin, P Burtin.   

Abstract

Cells from rat carcinoma cell lines PROb (giving progressive tumours) and REGb (giving regressive tumours) have cell surface receptors which bind specifically rat plasminogen and plasmin. Affinity for Pg was found to be higher in PROb (Kd = 10(-7) M) than in REGb cells (Kd = 5.10(-7) M) but with a concomitant decrease in the number of binding sites, 0.9 x 10(6)/cell (range from 0.6 to 1.2 x 10(6)) in PROb vs 3.6 x 10(6)/cell (range 1.2 to 6 x 10(6)) in REGb cells. The number and the affinity of binding sites varied in an opposite way in PROb and REGb cells. The difference in affinity parameters was unrelated to the degree of invasiveness of tumour cells in syngenetic rats. Bound plasmin retained its enzymatic activity, which indicates that its binding does not involve the catalytic active site. In cell solubilisates plasminogen receptor appeared as one major band situated in the area of 50-60 kDa.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1322156      PMCID: PMC1977915          DOI: 10.1038/bjc.1992.215

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  18 in total

1.  A receptor for plasminogen and plasmin on human and rat carcinoma cells. Evidence for strong interspecific reactivity.

Authors:  M Durliat; O Komano; P Correc; P Burtin
Journal:  Thromb Res       Date:  1991-12-15       Impact factor: 3.944

2.  Receptor mediated binding of the fibrinolytic components, plasminogen and urokinase, to peripheral blood cells.

Authors:  L A Miles; E F Plow
Journal:  Thromb Haemost       Date:  1987-10-28       Impact factor: 5.249

3.  The plasmin system in human colonic tumors: an immunofluorescence study.

Authors:  P Burtin; G Chavanel; J Andre
Journal:  Int J Cancer       Date:  1985-03-15       Impact factor: 7.396

4.  Limited proteolysis of tumor cells increases their plasmin-binding ability.

Authors:  M Camacho; M C Fondaneche; P Burtin
Journal:  FEBS Lett       Date:  1989-03-13       Impact factor: 4.124

5.  The presence of plasmin receptors on three mammary carcinoma MCF-7 sublines.

Authors:  P Correc; M C Fondanèche; M Bracke; P Burtin
Journal:  Int J Cancer       Date:  1990-10-15       Impact factor: 7.396

6.  Characterization of the cellular binding site for the urokinase-type plasminogen activator.

Authors:  A Estreicher; A Wohlwend; D Belin; W D Schleuning; J D Vassalli
Journal:  J Biol Chem       Date:  1989-01-15       Impact factor: 5.157

7.  Solubilization of the plasmin receptor from human carcinoma cells.

Authors:  P Burtin; M C Fondaneche
Journal:  Biochem Biophys Res Commun       Date:  1990-07-31       Impact factor: 3.575

8.  Selection by trypsin of two sublines of rat colon cancer cells forming progressive or regressive tumors.

Authors:  F Martin; A Caignard; J F Jeannin; A Leclerc; M Martin
Journal:  Int J Cancer       Date:  1983-11-15       Impact factor: 7.396

9.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

Authors:  P J Fraker; J C Speck
Journal:  Biochem Biophys Res Commun       Date:  1978-02-28       Impact factor: 3.575

10.  The plasmin system in human adenocarcinomas and their metastases. A comparative immunofluorescence study.

Authors:  P Burtin; G Chavanel; J André-Bougaran; A Gentile
Journal:  Int J Cancer       Date:  1987-02-15       Impact factor: 7.396

View more
  2 in total

Review 1.  New insights into the role of Plg-RKT in macrophage recruitment.

Authors:  Lindsey A Miles; Shahrzad Lighvani; Nagyung Baik; Caitlin M Parmer; Sophia Khaldoyanidi; Barbara M Mueller; Robert J Parmer
Journal:  Int Rev Cell Mol Biol       Date:  2014       Impact factor: 6.813

Review 2.  Plasminogen receptors: the first quarter century.

Authors:  Lindsey A Miles; Robert J Parmer
Journal:  Semin Thromb Hemost       Date:  2013-03-26       Impact factor: 4.180

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.